Incidence and Survival of Appendiceal Mucinous Neoplasms

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 40, Issue 6, 2017, Pages 569-573

  Shaib, Walid L ^a   Goodman, Michael ^b   Chen, Zhengjia ^a   Kim, Sungjin ^a   Brutcher, Edith ^a   Bekaii Saab, Tanios ^c   El Rayes, Bassel F ^a  

^a EMORY UNIVERSITY   (United States)

^b Department of Epidemiology ^*  (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

appendiceal mucinous neoplasm; incidence; survival; time

Indexed keywords

ADOLESCENT; ADULT; AGED; APPENDECTOMY; APPENDICEAL MUCINOUS NEOPLASM; APPENDIX TUMOR; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; HEMICOLECTOMY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; TOTAL COLON RESECTION; CANCER GRADING; COLLOID CARCINOMA; COLON RESECTION; INCIDENCE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APPENDECTOMY; APPENDICEAL NEOPLASMS; COLECTOMY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL RATE; YOUNG ADULT;

EID: 85036620952     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000210     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Smeenk RM, van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34:196-201.
3. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol. 1995;19:1390-1408.
4. Pai RK, Beck AH, Norton JA, et al. Appendiceal mucinous neoplasms: clinicopathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol. 2009;33:1425-1439.
5. Young RH. Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms. Semin Diagn Pathol. 2004;21:134-150.
6. Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27:1089-1103.
7. Gupta S, Parsa V, Adsay V, et al. Clinicopathological analysis of primary epithelial appendiceal neoplasms. Med Oncol. 2010;27: 1073-1078.
8. Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12:673-688.
9. Carr NJ, McCarthy WF, Sobin LH. Epithelial noncarcinoid tumors and tumor-like lesions of the appendix. A clinicopathologic study of 184 patients with a multivariate analysis of prognostic factors. Cancer. 1995;75:757-768.
10. Overman MJ, Fournier K, Hu CY, et al. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg. 2013;257:1072-1078.
11. Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer. 2001;92:85-91.
12. Misdraji J. Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med. 2010;134:864-870.
13. Miner TJ, Shia J, Jaques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241:300-308.
14. Sugarbaker PH, Graves T, DeBruijn EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res. 1990;50:5790-5794.
15. Chua TC, Moran BJ, Sugarbaker PH, et al. Early-and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449-2456.
16. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14:128-133.
17. Stewart JHT, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624-634.
18. Sirintrapun SJ, Blackham AU, Russell G, et al. Significance of signet ring cells in high-grade mucinous adenocarcinoma of the peritoneum from appendiceal origin. Hum Pathol. 2014;45: 1597-1604.
19. Raghav KP, Shetty AV, Kazmi SM, et al. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013;18:1270-1277.
20. van den Heuvel MG, Lemmens VE, Verhoeven RH, et al. The incidence of mucinous appendiceal malignancies: a populationbased study. Int J Colorectal Dis. 2013;28:1307-1310.
21. Shaib WL, Martin LK, Choi M, et al. Hyperthermic intraperitoneal chemotherapy following cytoreductive surgery improves outcome in patients with primary appendiceal mucinous adenocarcinoma: a pooled analysis from three tertiary care centers. Oncologist. 2015. [Epub ahead of print].
22. National Cancer Institute, SEER as a Research Resource. 2010. http://seer.cancer.gov/about/.
23. Prentice JKaR. The statistical analysis of failure time data 1980. First Edition, John Wiley & Sons, Inc., Hoboken, New Jersey.
24. Cox DR. Regression models and life tables. J R Stat Soc Ser. 1972; B:187-220.
25. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19: 335-351.
26. Statistical Methodology and Applications Branch and Data Modeling Branch, JoinPoint Regression Program, Version 4.0.4 (May 6, 2013). In Surveillance Research Program National Cancer Institute. 2013. www.cacer.org.
27. Edge S, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual. 7th ed. 2010;304(15) New York: Springer.
28. Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015;150:17-22.
29. Tarraga Lopez PJ, Albero JS, Rodriguez-Montes JA. Primary and secondary prevention of colorectal cancer. Clin Med Insights Gastroenterol. 2014;7:33-46.
30. Nathan H, Pawlik TM. Limitations of claims and registry data in surgical oncology research. Ann Surg Oncol. 2008;15:415-423.